The top 10 cosmeceuticals for facial hyperpigmentation.
arbutin
ferulic acid
kojic acid
melasma
nicotinamide
pigmentation
resorcinol
retinol
thiamidol
vitamin C
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
06
07
2020
revised:
21
07
2020
accepted:
22
07
2020
pubmed:
29
7
2020
medline:
15
5
2021
entrez:
29
7
2020
Statut:
ppublish
Résumé
Disorders of facial hyperpigmentation including melasma, postinflammatory hyperpigmentation and solar lentigines are common cutaneous conditions which can have a huge impact on patients' quality of life and often prove difficult to treat. The nascent market of cosmeceutical options provides a potentially safer and efficacious alternative for treating these challenging conditions. These can be used alone or in combination with other established treatments. Many cosmeceutical products are thought to work through inhibition of tyrosinase, a key enzyme of melanogenesis. We discuss the mode of action and provide an up-to-date review of the underlying evidence base for the top 10 cosmeceutical products for hyperpigmentation and melasma. Possible safer and more efficacious cosmeceutical therapies we discuss include thiamidol, kojic acid, vitamin C, arbutin, retinol, nicotinamide, ferulic acid, resorcinol, licorice root extract, and soy.
Substances chimiques
Cosmeceuticals
0
Monophenol Monooxygenase
EC 1.14.18.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14095Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Sarkar R, Arora P, Garg KV. Cosmeceuticals for hyperpigmentation: what is available? J Cutan Aesthet Surg. 2013;6(1):4-11.
Draelos ZD. Cosmeceuticals: What's real, What's not. Dermatol Clin. 2019;37(1):107-115.
Zolghadri S, Bahrami A, Hassan Khan MT, et al. A comprehensive review on tyrosinase inhibitors. J Enzyme Inhib Med Chem. 2019;34(1):279-309.
Mann T, Gerwat W, Batzer J, et al. Inhibition of human tyrosinase requires molecular motifs distinctively different from mushroom tyrosinase. J Invest Dermatol. 2018;138(7):1601-1608.
Arrowitz C, Schoelermann AM, Mann T, Jiang LI, Weber T, Kolbe L. Effective tyrosinase inhibition by thiamidol results in significant improvement of mild to moderate melasma. J Invest Dermatol. 2019;139(8):1691-1698.
Philipp-Dormston WG, Vila Echagüe A, Pérez Damonte SH, et al. Thiamidol containing treatment regimens in facial hyperpigmentation: an international multi-center approach consisting of a double-blind, controlled, split-face study and of an open label, real-world study. Int J Cosmet Sci. 2020;42:377-387. https://doi.org/10.1111/ics.12626.
Saeedi M, Eslamifar M, Khezri K. Kojic acid applications in cosmetic and pharmaceutical preparations. Biomed Pharmacother. 2019;110:582-593.
Saghaie L, Pourfarzam M, Fassihi A, Sartippour B. Synthesis and tyrosinase inhibitory properties of some novel derivatives of kojic acid. Res Pharm Sci. 2013;8(4):233-242.
Scientific Committee on Consumer Safety. European Commission. Opinion on kojic acid. (updated 26-27 June 2012; cited June 12, 2020). https://ec.europa.eu/health/sites/health/files/scientific_committees/consumer_safety/docs/sccs_o_098.pdf
Lim JT. Treatment of melasma using kojic acid in a gel containing hydroquinone and GA. Dermatol Surg. 1999;25(4):282-284.
Garcia A, Fulton JE Jr. The combination of GA and hydroquinone or kojic acid for the treatment of melasma and related conditions. Dermatol Surg. 1996;22(5):443-447.
Al-Niaimi F, Chiang NYZ. Topical vitamin C and the skin: mechanisms of action and clinical applications. J Clin Aesthet Dermatol. 2017;10(7):14-17.
Hwang SW, Oh DJ, Lee D, Kim JW, Park SW. Clinical efficacy of 25% L-ascorbic acid (C'ensil) in the treatment of melasma. J Cutan Med Surg. 2009;13(2):74-81.
Espinal-Perez LE, Moncada B, Castanedo-Cazares JP. A double-blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma. Int J Dermatol. 2004;43(8):604-607.
Handog EB, Galang DA, de Leon-Godinez MA, Chan GP. A randomized, double-blind, placebo-controlled trial of oral procyanidin with vitamins A, C, E for melasma among Filipino women. Int J Dermatol. 2009;48(8):896-901.
Menon A, Eram H, Kamath PR, Goel S, Babu AMA. Split face comparative study of safety and efficacy of microneedling with Tranexamic acid versus microneedling with vitamin C in the treatment of melasma. Indian Dermatol Online J. 2019;11(1):41-45.
Ismail ESA, Patsatsi A, Abd El-Maged WM, Nada EEAE. Efficacy of microneedling with topical vitamin C in the treatment of melasma. J Cosmet Dermatol. 2019;18:1342-1347. https://doi.org/10.1111/jocd.12878.
Taylor MB, Yanaki JS, Draper DO, Shurtz JC, Coglianese M. Successful short-term and long-term treatment of melasma and postinflammatory hyperpigmentation using vitamin C with a full-face iontophoresis mask and a mandelic/malic acid skin care regimen. J Drugs Dermatol. 2013;12(1):45-50.
Crocco EI, Veasey JV, Boin MF, Lellis RF, Alves RO. A novel cream formulation containing nicotinamide 4%, arbutin 3%, bisabolol 1%, and retinaldehyde 0.05% for treatment of epidermal melasma. Cutis. 2015;96(5):337-342.
Draelos ZD, ed. Ethnic skin and pigmentation. Cosmetics and Dermatologic Problems and Solutions. 3rd ed. Boca Raton, FL: CRC Press; 2011:52-55.
Morag M, Nawrot J, Siatkowski I, et al. A double-blind, placebo-controlled randomized trial of Serratulae quinquefoliae folium, a new source of β-arbutin, in selected skin hyperpigmentations. J Cosmet Dermatol. 2015;14(3):185-190.
Polnikorn N. Treatment of refractory melasma with the MedLite C6 Q-switched Nd: YAG laser and alpha arbutin: a prospective study. J Cosmet Laser Ther. 2010;12(3):126-131.
Zasada M, Budzisz E. Retinoids: active molecules influencing skin structure formation in cosmetic and dermatological treatments. Postepy Dermatol Alergol. 2019;36(4):392-397.
Rendon MI, Barkovic S. Clinical evaluation of a 4% hydroquinone + 1% retinol treatment regimen for improving melasma and photodamage in fitzpatrick skin types III-VI. J Drugs Dermatol. 2016;15(11):1435-1441.
Yoshimura K, Momosawa A, Aiba E, et al. Clinical trial of bleaching treatment with 10% all-trans retinol gel. Dermatol Surg. 2003;29(2):155-160.
Green C, Orchard G, Cerio R, et al. A clinicopathological study of the effects of topical retinyl propionate cream in skin photoageing. Clin Exp Dermatol. 1998;23:162-167.
Watson REB, Long SP, Bowden JJ, Bastrilles JY, Barton SP, Griffiths CE. Repair of photoaged dermal matrix by topical application of a cosmetic “antiageing” product. Br J Dermatol. 2008;158:472-477.
Sorg O, Kasraee B, Salomon D, Saurat JH. The potential depigmenting activity of retinaldehyde. Dermatology. 2013;227(3):231-237.
Dhaliwal S, Rybak I, Ellis SR, et al. Prospective, randomized, double-blind assessment of topical bakuchiol and retinol for facial photoageing. Br J Dermatol. 2019;180(2):289-296.
Forbat E, Al-Niaimi F, Ali FR. Use of nicotinamide in dermatology. Clin Exp Dermatol. 2017;42(2):137-144.
Navarrete-Solís J, Castanedo-Cázares JP, Torres-Álvarez B, et al. A double-blind, randomized clinical trial of Niacinamide 4% versus hydroquinone 4% in the treatment of Melasma. Dermatol Res Pract. 2011;2011:379173.
Zduńska K, Dana A, Kolodziejczak A, Rotsztejn H. Antioxidant properties of FA and its possible application. Skin Pharmacol Phys. 2018;31(6):332-336.
Ichihashi M, Funasaka Y, Ohashi A, et al. The inhibitory effect of DL-alpha-tocopheryl ferulate in lecithin on melanogenesis. Anticancer Res. 1999;19(5A):3769-3774.
Funasaka Y, Komoto M, Ichihashi M. Depigmenting effect of alpha-tocopheryl ferulate on normal human melanocytes. Pigment Cell Res. 2003;13(Suppl. 8):170-174.
Mazurek K, Pierzchała E. Comparison of efficacy of products containing azelaic acid in melasma treatment. J Cosmet Dermatol. 2016;15(3):269-282.
Kim J, Kim J, Lee YI, Almurayshid A, Jung JY, Lee JH. Effect of a topical antioxidant serum containing vitamin C, vitamin E, and FA after Q-switched 1064-nm Nd: YAG laser for treatment of environment-induced skin pigmentation. J Cosmet Dermatol. 2020. https://doi.org/10.1111/jocd.13323.
Kolbe L, Mann T, Gerwat W, et al. 4-n-butylresorcinol, a highly effective tyrosinase inhibitor for the topical treatment of hyperpigmentation. J Eur Acad Dermatol Venereol. 2013;27:19-23.
Okubo T, Oyohikawa M, Futaki K, Matsukami M, Fujii A. The inhibitory effects of 4-N-butyl-resorcinol on melanogenesis. J Dermatol Sci. 1995;10:88.
Kim DS, Kim SY, Park SH, et al. Inhibitory effects of 4-n-butylresorcinol on tyrosinase activity and melanin synthesis. Biol Pharm Bull. 2005;28:2216-2219.
Khemis A, Kaiafa A, Queille-Roussel C, Duteil L, Ortonne JP. Evaluation of efficacy and safety of rucinol serum in patients with melasma: a randomized controlled trial. Br J Dermatol. 2007;156(5):997-1004.
Huh SY, Shin JW, Na JI, Huh CH, Youn SW, Park KC. The efficacy and safety of 4-n-butylresorcinol 0.1% cream for the treatment of melasma: a randomized controlled split-face trial. Ann Dermatol. 2010;22(1):21-25.
Madan Mohan NT, Gowda A, Jaiswal AK, et al. Assessment of efficacy, safety, and tolerability of 4-n-butylresorcinol 0.3% cream: an Indian multicentric study on melasma. Clin Cosmet Investig Dermatol. 2016;9:21-27.
Sarkar R, Bansal S, Garg VK. Chemical peels for melasma in dark-skinned patients. J Cutan Aesthet Surg. 2012;5(4):247-253.
Simmler C, Pauli GF, Chen SN. Phytochemistry and biological properties of glabridin. Fitoterapia. 2013;90:160-184.
Yokota T, Nishio H, Kubota Y, Mizoguchi M. The inhibitory effect of glabridin from licorice extracts on melanogenesis and inflammation. Pigment Cell Res. 1998;11(6):355-361.
Zubair S, Mujtaba G. Comparison of efficacy of topical 2% liquiritin, topical 4% liquiritin and topical 4% hydroquinone in the management of melasma. J Pak Assoc Dermatol. 2009;19:158-163.
Amer M, Metwalli M. Topical liquiritin improves melasma. Int J Dermatol. 2000;39:299-301.
Costa A, Silva C, Arruda L, Zaniboni M, Cordero T, Moisés T. The association of emblica, licorice, and belides is an effective alternative to hydroquinone for the clinical treatment of melasma: P3205. J Am Acad Dermatol. 2010;62(3):AB119.
Seiberg M, Paine C, Sharlow E, et al. The protease-activated receptor 2 regulates pigmentation via keratinocyte-melanocyte interactions. Exp Cell Res. 2000;254:25-32.
Wallo W, Nebus J, Leyden JJ. Efficacy of a soy moisturizer in photoaging: a double-blind, vehicle-controlled, 12-week study. J Drugs Dermatol. 2007;6(9):917-922.
Hermanns JF, Petit L, Martalo O, Piérard-Franchimont C, Cauwenbergh G, Piérard GE. Unraveling the patterns of subclinical pheomelanin-enriched facial hyperpigmentation: effect of depigmenting agents. Dermatology. 2000;201(2):118-122.
Pierard G, Graf R, Gonzalez R, Cauwenbergh W. Effects of soy on hyperpigmentation in Caucasian and Hispanic populations. 59th Annual Meeting of the American Academy of Dermatology; March 2-7, 2001; Washington, DC